[go: up one dir, main page]

AR097866A1 - Derivados de 4-azaindol - Google Patents

Derivados de 4-azaindol

Info

Publication number
AR097866A1
AR097866A1 ARP140103638A ARP140103638A AR097866A1 AR 097866 A1 AR097866 A1 AR 097866A1 AR P140103638 A ARP140103638 A AR P140103638A AR P140103638 A ARP140103638 A AR P140103638A AR 097866 A1 AR097866 A1 AR 097866A1
Authority
AR
Argentina
Prior art keywords
hydrogen
halogen
alkoxy
alkyl
haloalkyl
Prior art date
Application number
ARP140103638A
Other languages
English (en)
Inventor
Payne Andrew
Luis Castro Pineiro Jose
Michelle Birch Louise
James BRAUNTON Alan
Edward Kitulagoda James
Soejima Motohiro
Khan Afzal
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of AR097866A1 publication Critical patent/AR097866A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 2: Un compuesto de la fórmula (1), o una sal aceptable para uso farmacéutico del mismo, caracterizado porque R¹ es hidrógeno, halógeno, ciano, alquilo C₁₋₄ o alcoxi C₁₋₄; R² es hidrógeno; p es 1 ó 2 y cada R⁴ se selecciona en forma independiente de halógeno, alquilo C₁₋₄, alcoxi C₁₋₄, haloalquilo C₁₋₄ y haloalcoxi C₁₋₄. Reivindicación 3: Un compuesto de la fórmula (2), o una sal aceptable para uso farmacéutico del mismo, caracterizado porque R¹ es hidrógeno, halógeno, alquilo C₁₋₄ o alcoxi C₁₋₄; R² es hidrógeno; R⁴ᵃ hidrógeno o halógeno; R⁴ᵇ es hidrógeno, halógeno, alquilo C₁₋₄, alcoxi C₁₋₄, haloalquilo C₁₋₄ o haloalcoxi C₁₋₄; R⁴ᶜ es hidrógeno, halógeno, alquilo C₁₋₄, alcoxi C₁₋₄ o haloalquilo C₁₋₄; R⁴ᵈ es hidrógeno o halógeno; en el que por lo menos uno de R⁴ᵃ, R⁴ᵇ, R⁴ᶜ y R⁴ᵈ es distinto de hidrógeno y no más de dos de R⁴ᵃ, R⁴ᵇ, R⁴ᶜ y R⁴ᵈ son hidrógeno.
ARP140103638A 2013-10-01 2014-10-01 Derivados de 4-azaindol AR097866A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1317363.8A GB201317363D0 (en) 2013-10-01 2013-10-01 Novel compounds

Publications (1)

Publication Number Publication Date
AR097866A1 true AR097866A1 (es) 2016-04-20

Family

ID=49585123

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140103638A AR097866A1 (es) 2013-10-01 2014-10-01 Derivados de 4-azaindol

Country Status (21)

Country Link
US (3) US20150094328A1 (es)
EP (2) EP3052496B1 (es)
JP (3) JP6517790B2 (es)
KR (1) KR102248559B1 (es)
CN (1) CN105873927B (es)
AR (1) AR097866A1 (es)
AU (1) AU2014330880B2 (es)
BR (1) BR112016007016A8 (es)
CA (1) CA2924619C (es)
CL (1) CL2016000726A1 (es)
ES (2) ES2807221T3 (es)
GB (1) GB201317363D0 (es)
HK (1) HK1223090A1 (es)
IL (1) IL244609B (es)
MX (1) MX368956B (es)
PE (1) PE20160839A1 (es)
PH (1) PH12016500529A1 (es)
RU (1) RU2688938C2 (es)
SG (1) SG11201602052YA (es)
TW (1) TW201546070A (es)
WO (1) WO2015049574A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
UA122391C2 (uk) 2014-04-23 2020-11-10 Такеда Фармасьютікал Компані Лімітед Похідні ізоіндолін-1-ону як позитивні алоестеричні модулятори холінергічного мускаринового рецептора м1 для лікування хвороби альцгеймера
US10208046B2 (en) 2014-05-16 2019-02-19 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
SMT201900213T1 (it) * 2015-06-08 2019-05-10 Suven Life Sciences Ltd Modulatori allosterici positivi del recettore muscarinico m1
NZ740587A (en) * 2015-09-10 2019-07-26 Suven Life Sciences Ltd Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators
EA201891854A1 (ru) 2016-02-16 2019-01-31 Вандербилт Юниверсити Положительные аллостерические модуляторы мускаринового ацетилхолинового рецептора m
WO2018063552A1 (en) 2016-09-30 2018-04-05 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
AU2018353544B2 (en) * 2017-10-18 2020-09-17 Suven Life Sciences Limited Heteroaryl compounds as muscarinic M1 receptor positive allosteric modulators
BR112020008050A2 (pt) * 2017-10-27 2020-11-03 Suven Life Sciences Limited composto modulador alostérico positivo de receptor muscarínico m1, composição farmacêutica compreendendo o referido composto, uso dos mesmos e combinação
US12065433B2 (en) 2018-10-24 2024-08-20 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M1
KR102347368B1 (ko) * 2020-11-03 2022-01-07 (주)케이메디켐 신규한 아자인돌 유도체, 이의 제조방법 및 이를 포함하는 인지기능 개선용 조성물
CN118440041B (zh) * 2024-07-02 2024-09-27 苏州凯瑞医药科技有限公司 一种手性4-氨基-3-羟基四氢吡喃的制备方法

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420521D0 (en) 1994-10-12 1994-11-30 Smithkline Beecham Plc Novel compounds
US6063930A (en) 1996-04-03 2000-05-16 Merck & Co., Inc. Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
WO2003044018A1 (en) 2001-11-19 2003-05-30 Neurogen Corporation 1h-pyrrolo[3,2-b]pyridine-3-carboxylic acid amides
GB0222743D0 (en) 2002-10-01 2002-11-06 Celltech R&D Ltd Chemical compounds
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
EP1615667A2 (en) 2003-04-11 2006-01-18 Novo Nordisk A/S Combinations of an 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist
EP1787982B1 (en) 2003-04-11 2010-05-12 High Point Pharmaceuticals, LLC 11Beta-Hydroxysteroid dehydrogenase type 1 active compounds
WO2004089416A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent
EP1853261B1 (de) 2005-03-03 2017-01-11 Universität des Saarlandes Selektive hemmstoffe humaner corticoidsynthasen
FR2890072A1 (fr) * 2005-09-01 2007-03-02 Fournier S A Sa Lab Nouveaux composesde pyrrolopyridine
EP1979353A2 (en) 2006-01-19 2008-10-15 OSI Pharmaceuticals, Inc. Fused heterobicyclic kinase inhibitors
US7964728B2 (en) 2006-07-06 2011-06-21 Solvay Pharmaceuticals B.V. Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition
EP2086531A4 (en) 2006-11-30 2009-09-30 Amira Pharmaceuticals Inc COMPOSITIONS AND TREATMENTS COMPRISING 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITORS AND NITRIC OXIDE MODULATORS
BRPI0812594A2 (pt) 2007-08-10 2015-06-23 Lundbeck & Co As H Composto ou sal ou hidrato do mesmo, composição farmacêutica, métodos para modulação da atividade de um receptor p2x7, para tratamento de uma condição responsiva á modulação do receptor p2x7 em um paciente, para inibição de morte de células gangliônicas retinais em um paciente, para determinação da presença ou ausência de receptor p2x7 em uma amostra, preparação farmacêutica acondicionada, e, uso de um composto ou sal ou hidrato do mesmo.
ATE541845T1 (de) 2007-08-29 2012-02-15 Schering Corp 2,3-substituierte azaindolderivate zur behandlung von virusinfektionen
AU2009206580A1 (en) * 2008-01-25 2009-07-30 Merck Sharp & Dohme Corp. Quinolizidinone M1 receptor positive allosteric modulators
CN101970437B (zh) 2008-01-31 2013-04-03 赛诺菲-安万特 环状氮杂吲哚-3-甲酰胺、其制备和其作为药物的用途
WO2009121033A2 (en) 2008-03-27 2009-10-01 University Of Southern California Substituted nitrogen heterocycles and synthesis and uses thereof
CA2685716A1 (en) 2008-04-04 2009-10-08 Summit Corporation Plc Compounds for treating muscular dystrophy
US8012992B2 (en) 2008-06-30 2011-09-06 Allergan, Inc. Aza-indoles and related compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
PE20110368A1 (es) 2008-08-18 2011-06-13 Univ Yale Moduladores de mif
WO2010033980A2 (en) 2008-09-22 2010-03-25 Isis Innovation Ltd. 4-azaindole bisphosphonates
MX2011005284A (es) 2008-11-20 2011-06-17 Merck Sharp & Dohme Moduladores de aril metil benzoquinazolinona alostericos positivos del receptor m1.
MX2011005597A (es) 2008-12-05 2011-06-16 Hoffmann La Roche Pirrolopirazinil-ureas como inhibidores de cinasas.
CN102325752B (zh) 2008-12-19 2015-02-04 百时美施贵宝公司 咔唑和咔啉激酶抑制剂
CA2750708A1 (en) 2009-02-23 2010-08-26 Merck Sharp & Dohme Corp. Pyrazolo [4,3-c] cinnolin-3-one m1 receptor positive allosteric modulators
WO2010123716A1 (en) 2009-04-20 2010-10-28 Merck Sharp & Dohme Corp. Heterocyclic fused cinnoline m1 receptor positive allosteric modulators
JP2012211085A (ja) 2009-08-12 2012-11-01 Kyowa Hakko Kirin Co Ltd ヘッジホッグシグナル阻害剤
AU2010288553A1 (en) * 2009-08-26 2012-04-12 Takeda Gmbh Methylpyrrolopyridinecarboxamides
CA2770480C (en) 2009-08-31 2014-11-18 Merck Sharp & Dohme Corp. Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
EP2512245B1 (en) 2009-12-14 2014-07-23 Merck Sharp & Dohme Corp. Pyridoquinazolinone m1 receptor positive allosteric modulators
CN102651970B (zh) * 2009-12-17 2014-11-12 默沙东公司 喹啉酰胺m1受体正性变构调节剂
US8383638B2 (en) 2009-12-21 2013-02-26 Merck Sharp & Dohme Aminobenzoquinazolinone M1 receptor positive allosteric modulators
AU2010333893A1 (en) 2009-12-23 2012-07-19 Sanofi [4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1H-pyrrolo-pyridin-yl)-methanones and synthesis thereof
EP2575454B1 (en) 2010-05-28 2018-08-29 Merck Sharp & Dohme Corp. Naphthalene carboxamide m1 receptor positive allosteric modulators
WO2011159553A1 (en) * 2010-06-15 2011-12-22 Merck Sharp & Dohme Corp. Heterocyclic fused phenanthrolinone m1 receptor positive allosteric modulators
US8815902B2 (en) * 2010-06-15 2014-08-26 Merck Sharp & Dohme Corp. Tetrahydroquinoline amide M1 receptor positive allosteric modulators
US8697690B2 (en) 2010-07-01 2014-04-15 Merck Sharp & Dohme Corp. Isoindolone M1 receptor positive allosteric modulators
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
US8664234B2 (en) 2010-10-04 2014-03-04 Merck Sharp & Dohme Corp. Dihydrobenzoquinazolinone M1 receptor positive allosteric modulators
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
DK2675893T3 (en) 2011-02-18 2019-04-15 Scripps Research Inst Directed differentiation of oligodendrocyte precursor cells into a myelinating cell fate
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
US20130072473A1 (en) 2011-05-09 2013-03-21 Proteostasis Therapeutics, Inc. Compounds for treating protein folding disorders
US9206200B2 (en) 2011-05-17 2015-12-08 Merck Sharp & Dohme Corp. N-linked lactam M1 receptor positive allosteric mogulators
WO2012158474A1 (en) 2011-05-17 2012-11-22 Merck Sharp & Dohme Corp. N-linked quinolineamide m1 receptor positive allosteric modulators
US9284312B2 (en) 2011-05-17 2016-03-15 Merck Sharp & Dohme Corp. N-methyl tetrahydroquinoline M1 receptor positive allosteric modulators
EP2770997B1 (en) 2011-10-28 2016-09-14 Vanderbilt University Substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m1
CN104039789B (zh) 2011-12-22 2016-09-07 默克专利股份有限公司 四氮杂-环戊二烯并[a]茚基及其作为正向变构调节剂的用途
WO2013106795A1 (en) * 2012-01-12 2013-07-18 Vanderbilt University Substituted 4-(1h~pyrazol-4.yl)benzyl analogues as positive allosteric modulators of machr m1 receptors
CA2918487C (en) * 2013-07-17 2021-08-03 Global Alliance For Tb Drug Development Azaindole compounds, synthesis thereof, and methods of using the same
TW201512197A (zh) * 2013-08-30 2015-04-01 Hoffmann La Roche 吡咯并吡啶或吡唑并吡啶衍生物
EP3049391B1 (en) * 2013-09-27 2018-12-26 F.Hoffmann-La Roche Ag Indole and indazole derivatives
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds

Also Published As

Publication number Publication date
CA2924619A1 (en) 2015-04-09
KR102248559B1 (ko) 2021-05-04
RU2016116775A3 (es) 2018-06-27
BR112016007016A8 (pt) 2020-02-27
JP2016531890A (ja) 2016-10-13
US9926312B2 (en) 2018-03-27
EP3489237A1 (en) 2019-05-29
RU2688938C2 (ru) 2019-05-23
JP6517790B2 (ja) 2019-05-22
CA2924619C (en) 2021-12-07
EP3052496B1 (en) 2018-11-28
CL2016000726A1 (es) 2016-09-23
PH12016500529A1 (en) 2016-05-16
CN105873927B (zh) 2017-11-28
US10072005B2 (en) 2018-09-11
KR20160072133A (ko) 2016-06-22
AU2014330880B2 (en) 2019-01-31
IL244609A0 (en) 2016-04-21
PE20160839A1 (es) 2016-08-20
MX2016004014A (es) 2016-09-21
CN105873927A (zh) 2016-08-17
JP2019112433A (ja) 2019-07-11
BR112016007016A2 (pt) 2017-08-01
US20160244445A1 (en) 2016-08-25
AU2014330880A1 (en) 2016-04-07
US20150094328A1 (en) 2015-04-02
IL244609B (en) 2019-12-31
EP3489237B1 (en) 2020-05-13
ES2710190T3 (es) 2019-04-23
SG11201602052YA (en) 2016-04-28
HK1223090A1 (zh) 2017-07-21
RU2016116775A (ru) 2017-11-09
JP6899944B2 (ja) 2021-07-07
TW201546070A (zh) 2015-12-16
EP3052496A1 (en) 2016-08-10
ES2807221T3 (es) 2021-02-22
WO2015049574A1 (en) 2015-04-09
GB201317363D0 (en) 2013-11-13
MX368956B (es) 2019-10-23
US20180208593A1 (en) 2018-07-26
JP2020143100A (ja) 2020-09-10

Similar Documents

Publication Publication Date Title
AR097866A1 (es) Derivados de 4-azaindol
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
SI3066085T1 (sl) Postopek sinteze inhibitorja indolamina 2,3-dioksigenaze
DOP2015000251A (es) Derivados de naftiridina utiles como antagonistas de la alfa-v-beta-6 integrina
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
CR20160098A (es) Polimorfo de los inhibidores de la syk
CR20150418A (es) Compuestos de tetrahidropirrolotiazina
UA113643C2 (xx) N-цикліламіди як нематоциди
EA201690473A1 (ru) Комбинированный состав двух противовирусных соединений
CR20160099A (es) Formulación de inhibidores de la syk
UA116467C2 (uk) Модулятори p2x7
AR091519A1 (es) Inhibidores pirrolopirazona de tanquirasa
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
RS54730B1 (sr) Inhibitori beta sekretaze
EA201691982A1 (ru) 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов
AR097253A1 (es) Derivado de pirazolilpirazol sustituido y el uso del mismo como herbicida
AR089753A1 (es) Derivados de amida heterociclicos como antagonistas del receptor p2x7
AR089623A1 (es) Inhibidores de iap
AR102957A1 (es) Combinaciones de compuestos activos
EA201591645A1 (ru) Hантагонисты, имеющие феноксипиперидиновое ядро в структуре
CL2017000151A1 (es) Derivados de piridona
AR091888A1 (es) Compuestos de urea y su uso como inhibidores de enzimas
ES2571577T3 (es) Derivados novedosos de morfolinilo útiles como inhibidores de MOGAT-2
AR098037A1 (es) Derivados de piperazina y su uso como medicamento
AR095330A1 (es) Azoles n-,c-disustituidos y composiciones y métodos para controlar plagas de nematodos

Legal Events

Date Code Title Description
FB Suspension of granting procedure